About Transducin beta-like protein 2
Transducin beta-like protein 2 (TBL2) is a protein
from Homo sapiens identified by UniProt accession
Q9Y4P3, 447 residues long.
MolForge cross-references it against 0 known binders and
134 disease associations.
Target properties
| Protein name | Transducin beta-like protein 2 |
| UniProt accession | Q9Y4P3 |
| Gene | TBL2 |
| Organism | Homo sapiens |
| Length | 447 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (134)
Diseases linked to this target (Open Targets).
- triglyceride measurement · score 0.36
- blood protein measurement · score 0.27
- mean corpuscular volume · score 0.27
- physical activity · score 0.23
- diacylglycerol 34:3 measurement · score 0.23
- alkaline phosphatase measurement · score 0.22
- gout · score 0.21
- sphingomyelin measurement · score 0.21
- serum alanine aminotransferase measurement · score 0.20
- cystatin C measurement · score 0.19
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9Y4P3-F1 | alphafold | PREDICTED | 87.10 | — |
Amino-acid sequence (447 residues)
MELSQMSELM GLSVLLGLLA LMATAAVARG WLRAGEERSG RPACQKANGF PPDKSSGSKK QKQYQRIRKE KPQQHNFTHR LLAAALKSHS GNISCMDFSS NGKYLATCAD DRTIRIWSTK DFLQREHRSM RANVELDHAT LVRFSPDCRA FIVWLANGDT LRVFKMTKRE DGGYTFTATP EDFPKKHKAP VIDIGIANTG KFIMTASSDT TVLIWSLKGQ VLSTINTNQM NNTHAAVSPC GRFVASCGFT PDVKVWEVCF GKKGEFQEVV RAFELKGHSA AVHSFAFSND SRRMASVSKD GTWKLWDTDV EYKKKQDPYL LKTGRFEEAA GAAPCRLALS PNAQVLALAS GSSIHLYNTR RGEKEECFER VHGECIANLS FDITGRFLAS CGDRAVRLFH NTPGHRAMVE EMQGHLKRAS NESTRQRLQQ QLTQAQETLK SLGALKK
Explore Transducin beta-like protein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets